{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:42:49Z","timestamp":1794562969786,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j intensive care"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The optimal strategy for discontinuing arginine vasopressin and norepinephrine in patients recovering from shock remains uncertain. Although prior studies have suggested a higher risk of hypotension when arginine vasopressin is discontinued first, these findings may have been influenced by baseline imbalances and tapering practices. We conducted a retrospective study to evaluate whether the order of discontinuation between arginine vasopressin and norepinephrine was associated with the incidence of hypotension during the recovery phase of shock, with vasopressor end doses converted to norepinephrine equivalents for analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was a single-center retrospective cohort study of intensive care unit patients with shock who received both arginine vasopressin and norepinephrine from August 2017 to March 2024. Patients were categorized based on whether arginine vasopressin or norepinephrine was discontinued first. The primary outcome was the incidence of hypotension within 24\u00a0h of vasopressor cessation, defined as mean arterial pressure\u2009&lt;\u200960\u00a0mmHg requiring a\u2009\u2265\u200925% increase in the remaining vasopressor, reinstitution of the stopped agent, or a bolus of\u2009\u2265\u2009500\u00a0mL crystalloid or 25\u00a0g albumin. Overlap weighting using propensity scores was applied to adjust for baseline imbalances both in the overall cohort and in the septic shock subgroup. Propensity scores were estimated using logistic model, including baseline characteristics, hemodynamic parameters, and vasopressor end doses in norepinephrine equivalents.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 524 patients were analyzed, with 293 discontinuing AVP first and 231 discontinuing NE first. In the unadjusted cohorts, hypotension occurred in 19% of the AVP-first group and 26% of the NE-first group. After overlap weighting, all baseline covariates were balanced between the groups, and the incidence of hypotension was not significantly different (19% vs 21%, <jats:italic>P<\/jats:italic>\u2009=\u20090.59). In the septic shock subgroup (<jats:italic>n<\/jats:italic>\u2009=\u2009267), the weighted analysis showed no significant difference in the incidence of hypotension between groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In patients recovering from shock who received both arginine vasopressin and norepinephrine, discontinuing arginine vasopressin first was not associated with a higher risk of hypotension.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40560-025-00823-w","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:42:31Z","timestamp":1759236151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Strategies for discontinuing vasopressin and norepinephrine during the recovery phase of shock: a single-center retrospective study"],"prefix":"10.1186","volume":"13","author":[{"given":"Shiho","family":"Suganuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehiko","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sasabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinshu","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"823_CR1","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1056\/NEJMra1208943","volume":"369","author":"JL Vincent","year":"2013","unstructured":"Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369:1729\u201334.","journal-title":"N Engl J Med"},{"key":"823_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/01.CCM.0000201896.45809.E3","volume":"34","author":"Y Sakr","year":"2006","unstructured":"Sakr Y, Reinhart K, Vincent JL, Sprung CL, Moreno R, Ranieri VM, et al. Dose dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med. 2006;34:589\u201397.","journal-title":"Crit Care Med"},{"key":"823_CR3","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00134-019-05801-z","volume":"45","author":"JA Russell","year":"2019","unstructured":"Russell JA. Vasopressor therapy in critically ill patients with shock. Intensive Care Med. 2019;45:1503\u201317.","journal-title":"Intensive Care Med"},{"key":"823_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40360-016-0063-z","volume":"17","author":"C Thongrayoon","year":"2016","unstructured":"Thongrayoon C, Cheungpasitporn W, Harrison AM, Carrera P, Srivali N, Kittamongkolchai W, et al. Temporal trends in the utilization of vasopressors in intensive care units: an epidemiologic study. BMC pharmacol Toxicol. 2016;17:19.","journal-title":"BMC pharmacol Toxicol"},{"key":"823_CR5","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49:e1063\u2013143.","journal-title":"Crit Care Med"},{"key":"823_CR6","doi-asserted-by":"publisher","first-page":"362e7","DOI":"10.1016\/j.jcrc.2009.10.005","volume":"25","author":"SR Bauer","year":"2010","unstructured":"Bauer SR, Aloi JJ, Ahrens CL, Yeh JY, Culver DA, Reddy AJ. Discontinuation of vasopressin before norepinephrine increase the incidence of hypotension in patients recovering from septic shock; a retrospective cohort study. J Crit Care. 2010;25:362e7-411.","journal-title":"J Crit Care"},{"key":"823_CR7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/1060028018765187","volume":"52","author":"N Musallam","year":"2018","unstructured":"Musallam N, Altshuler D, Merchan C, Zakhary B, Aberle C, Papadopopulos J. Evaluating vasopressor discontinuation strategies in patients with septic shock on concomitant norepinephrine and vasopressin infusions. Ann Pharmacother. 2018;52:733\u20139.","journal-title":"Ann Pharmacother"},{"key":"823_CR8","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1177\/0885066617714209","volume":"34","author":"DA Hammond","year":"2019","unstructured":"Hammond DA, MacCain K, Painter JT, Clem OA, Cullen J, Brotherton AL, et al. Discontinuation of vasopressin before norepinephrine in the recovery phase of septic shock. J Intensive Care Med. 2019;34:805\u201310.","journal-title":"J Intensive Care Med"},{"key":"823_CR9","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1177\/0885066617716396","volume":"34","author":"BD Bissell","year":"2019","unstructured":"Bissell BD, Magee C, Moran P, Thompson Bastin ML, Flannery AH. Hemodynamic instability secondary to vasopressin withdrawal in septic shock. J Intensive Care Med. 2019;34:761\u20135.","journal-title":"J Intensive Care Med"},{"key":"823_CR10","doi-asserted-by":"publisher","first-page":"16680","DOI":"10.1038\/s41598-021-96322-7","volume":"11","author":"X Song","year":"2021","unstructured":"Song X, Liu X, Evans KD, Frank RD, Barreto EF, Dong Y, et al. The order of vasopressor discontinuation and incidence of hypotension: a retrospective cohort analysis. Sci Rep. 2021;11:16680.","journal-title":"Sci Rep"},{"key":"823_CR11","first-page":"250","volume":"188","author":"F Li","year":"2019","unstructured":"Li F, Thomas LE, Li F. Addressing extreme propensity scores via the overlap weights. Am J Epidemiol. 2019;188:250\u20137.","journal-title":"Am J Epidemiol"},{"key":"823_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13054-023-04322-y","volume":"27","author":"Y Kotani","year":"2023","unstructured":"Kotani Y, Gioia AD, Landoni G, Belletti A, Khanna AK. An updated \u201cnorepinephrine equivalent\u201d score in intensive care as a marker of shock severity. Crit Care. 2023;27:29.","journal-title":"Crit Care"},{"key":"823_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/SHK.0000000000001609","volume":"55","author":"SW Lam","year":"2021","unstructured":"Lam SW, Sacha GL, Duggal A, Reddy AJ, Bauer SR. Abrupt discontinuation versus down-titration of vasopressin in patients recovering from septic shock. Shock. 2021;55:210\u20134.","journal-title":"Shock"},{"key":"823_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/phar.2082","volume":"38","author":"GL Sacha","year":"2018","unstructured":"Sacha GL, Lam SW, Duggal A, Torbic H, Reddy AJ, Bauer SR. Hypotension risk based on vasoactive agent discontinuation order in patients in the recovery phase of septic shock. Pharmacotherapy. 2018;38:319\u201326.","journal-title":"Pharmacotherapy"},{"key":"823_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/10600280251335344","author":"S Starkel","year":"2025","unstructured":"Starkel S, Schuler BR, Kovacevic MP, DeGrado JR, Szumita PM, Dube KM. Evaluating rebound hypotension following vasopressor discontinuation strategies in patients with septic shock. Ann Pharmocother. 2025. https:\/\/doi.org\/10.1177\/10600280251335344.","journal-title":"Ann Pharmocother"},{"key":"823_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.medine.2025.502147","author":"C Mallmann","year":"2025","unstructured":"Mallmann C, Galiotto TMB, de Oliveira MS, Moraes RB. Reduction of norepinephrine versus vasopressin in the stabilization phase of septic shock: RENOVA clinical trial. Med Intensiva (Engl Ed). 2025. https:\/\/doi.org\/10.1016\/j.medine.2025.502147.","journal-title":"Med Intensiva (Engl Ed)"},{"key":"823_CR17","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa067373","volume":"358","author":"JA Russell","year":"2008","unstructured":"Russell JA, Walley KR, Singer J, Gordon AC, H\u00e9bert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877\u201387.","journal-title":"N Engl J Med"},{"key":"823_CR18","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0022-5223(98)70049-2","volume":"116","author":"M Argenziano","year":"1998","unstructured":"Argenziano M, Chen JM, Choudhri AF, Cullinane S, Garfein E, Weinnberg AD, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg. 1998;116:973\u201380.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"823_CR19","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1161\/01.CIR.0000066692.71008.BB","volume":"107","author":"MW D\u00fcnser","year":"2003","unstructured":"D\u00fcnser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107:2313\u20139.","journal-title":"Circulation"},{"key":"823_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/ALN.0000000000001434","volume":"126","author":"LA Hajjar","year":"2017","unstructured":"Hajjar LA, Vincent JL, Galas FRBG, Rhodes A, Landoni G, Osawa EA, et al. Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: The VANCS randomized controlled trial. Anesthesiology. 2017;126:85\u201393.","journal-title":"Anesthesiology"},{"key":"823_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/jac5.1079","volume":"2","author":"DA Hammond","year":"2019","unstructured":"Hammond DA, Rech MA, Daley MJ, Devlin JW, Hodge EK, Kooda KJ, et al. Perceptions regarding vasopressin use and practices in septic shock, and cost containment strategies. J Am Coll Clin Pharm. 2019;2:257\u201367.","journal-title":"J Am Coll Clin Pharm"},{"key":"823_CR22","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1161\/01.CIR.95.5.1122","volume":"95","author":"DW Landry","year":"1997","unstructured":"Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D\u2019Alessandro D, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95:1122\u20135.","journal-title":"Circulation"},{"key":"823_CR23","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1097\/01.CCM.0000063046.82359.4A","volume":"31","author":"T Sharshar","year":"2003","unstructured":"Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D. Circulating vasopressin levels in septic shock. Crit Care Med. 2003;31:1752\u20138.","journal-title":"Crit Care Med"},{"key":"823_CR24","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1097\/00003246-199708000-00012","volume":"25","author":"DW Landry","year":"1997","unstructured":"Landry DW, Levin HR, Gallant EM, Seo S, D\u2019Alessandro D, Oz MC, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med. 1997;25:1279\u201382.","journal-title":"Crit Care Med"},{"key":"823_CR25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1164\/rccm.201006-0972CI","volume":"183","author":"SM Hollenberg","year":"2011","unstructured":"Hollenberg SM. Vasoactive drugs in circulatory shock. Am J Respir Crit Care Med. 2011;183:847\u201355.","journal-title":"Am J Respir Crit Care Med"},{"key":"823_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/00000539-200107000-00003","volume":"93","author":"MW D\u00fcnser","year":"2001","unstructured":"D\u00fcnser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg. 2001;93:7\u201313.","journal-title":"Anesth Analg"},{"issue":"Suppl 9","key":"823_CR27","first-page":"286II","volume":"96","author":"M Argenziano","year":"1997","unstructured":"Argenziano M, Choudhri AF, Oz MC, Rose EA, Smith CR, Landry DW. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation. 1997;96(Suppl 9):286II-II290.","journal-title":"Circulation"},{"key":"823_CR28","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s00134-019-05912-7","volume":"46","author":"PY Olivier","year":"2020","unstructured":"Olivier PY, Moal V, Saulnier P, Lasocki S, Radermacher P, Asfar P. Renin aldosterone vasopressin and copeptin kinetics in patients with septic shock, a post-hoc Hyper2S randomized trial analysis. Intensive Care Med. 2020;46:808\u201310.","journal-title":"Intensive Care Med"},{"key":"823_CR29","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1378\/chest.120.3.989","volume":"120","author":"CL Holmes","year":"2001","unstructured":"Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest. 2001;120:989\u20131002.","journal-title":"Chest"}],"container-title":["Journal of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40560-025-00823-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40560-025-00823-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40560-025-00823-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:42:38Z","timestamp":1759236158000},"score":1,"resource":{"primary":{"URL":"https:\/\/jintensivecare.biomedcentral.com\/articles\/10.1186\/s40560-025-00823-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["823"],"URL":"https:\/\/doi.org\/10.1186\/s40560-025-00823-w","relation":{},"ISSN":["2052-0492"],"issn-type":[{"value":"2052-0492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of the Jichi Medical University Saitama Medical Center (No. S24-144). Informed consent was obtained through an opt-out process in accordance with institutional policy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}